Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

uniQure, Benitec ink cross-licensing RNAi agreement
January 2013
SHARING OPTIONS:

AMSTERDAM, The Netherlands—uniQure and Benitec Biopharma, an Australian biotechnology company focused on gene silencing, have entered into a non-exclusive cross-licensing agreement, which grants uniQure access to Benitec's DNA-directed RNA interference (ddRNAi) technology in Huntington's disease, while Benitec receives nonexclusive access to uniQure's AAV5 delivery technology for the development of a ddRNAi therapy for hepatitis B.  
 
"While our current programs focus on delivering fully functioning therapeutic genes to remedy faulty or malfunctioning genes, Benitec's ddRNAi technology will allow us to do the opposite—to silence the gene responsible for producing the mutant protein that lies at the basis of Huntington's disease, and to develop a therapy for this devastating disease," Jörn Aldag, CEO of uniQure, said in a press release regarding the deal.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.